Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy

NCT ID: NCT02347683

Last Updated: 2023-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2016-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The optimal timing to measure thyroglobulin(Tg) after thyroidectomy is unknown in patients with thyroid cancer. The ATA and NCCN guidelines are not specific on optimal timing of Tg levels in post-op state and suggest anywhere between 2-12 weeks.

Hypothesis - Post -op Tg nadirs at 6-8 weeks .

Primary Objective -Determine optimal timing of post thyroidectomy Tg nadir, so to determine the most accurate time to check post operatively.

Secondary Outcome - Determine factors that will affect Tg levels post operatively.

All adults age 19 and above already planning to undergo near total /total thyroidectomy for reasons unrelated to the study.

Measure Tg , Tg Ab and TSH pre-op, post op ---\> 7-14 days, 4 wk, 6 wk, and 3 month in patients with pathology confirmed benign disease.

Measure Tg , Tg Ab , TSH pre-op, post op ---\> 7-14 days, 4 wk, 6 wk, 3 month, 6 month, and 12 month in patients with thyroid cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thyroid cancer, the most common endocrine tumor, constitutes 3.8% of all cancers. 62,980 new cases were estimated in the U.S. in 20141, an increasing trend from the 37,200 new cases in 20092. 90% of all thyroid cancers are differentiated thyroid carcinomas (DTC), which include both papillary and follicular thyroid carcinoma3.

Management of DTC involves a total thyroidectomy, with possible central and lateral neck dissection if there are clinical lymph node involvement, except for low-risk lesions that are unifocal, intrathyroidal, node-negative and measuring less than 1 cm in size. Radioactive iodine ablation of any remnant thyroid tissue may follow a total thyroidectomy depending on the risk stratification of the patient3. As for any cancer, management of thyroid cancer involves long-term surveillance for early detection of disease recurrence3.

According to the ATA guidelines, postoperative surveillance includes regular (every 6 to 12 months) clinical evaluation for tumor recurrence, evaluation with neck ultrasound and serum Thyroglobulin (Tg) levels while on levothyroxine replacement3. Serum Tg has become a very useful and well-acknowledged marker in patients with thyroid cancer post thyroidectomy for disease persistence, metastasis or recurrence.

Thyroglobulin is a 660 kDa dimeric glycoprotein that is exclusively produced and stored by thyroid follicular cells in benign conditions, but also by well-differentiated thyroid cancer cells4. A total thyroidectomy for higher risk patients is thus not only is important to provide definitive treatment and decrease risk of recurrence, but also allows for long term follow-up with Tg levels.

One study has reported Tg is eliminated through the liver and its half-life following total thyroidectomy has been reported to be about 65.2 hours. The Tg level was noted to decrease to less than 5-10 ng/ml 25 days after thyroidectomy, or after 7 to 10 half-lives in 11 patient samples5. Detection of Tg following the total thyroidectomy during long-term surveillance would therefore suggest persistent thyroid tissue.

Despite the determined half-life of Tg, in a retrospective study with 36 patients with low-risk papillary thyroid carcinoma, the unstimulated Tg level fell to \< 0.5 ng/ml after 6 months postoperatively in only 61%, and after 2 years postoperatively in 100% of the patients6. No prospective studies have yet determined the nadir of the Tg level post thyroidectomy. In our personal clinical experience, unstimulated serum Tg levels may be found undetectable 6 to 12 weeks following a total thyroidectomy.

The sensitivity, specificity, positive predictive value and negative predictive value of unstimulated (normal or low TSH ) serum Tg in assessing completeness of thyroidectomy (\< 0.5 ng/ml) have been reported to be 70%, 100%, 100% and 92% respectively6. Obtaining a basal unstimulated serum Tg level post thyroidectomy not only determines the completeness of the total thyroidectomy7, but also provides a basal level for future comparison during long-term surveillance. The high negative predictive value allows for the identification of patients less likely to have disease recurrence and provide less aggressive and more cost effective management strategies3.

The optimal time to obtain an unstimulated serum Tg level has not yet been determined. Obtaining the Tg level too early following the total thyroidectomy may result in a misleadingly significant Tg level and erroneously suggest residual disease, thereby leading to unnecessary further investigation and more aggressive management strategies. NCCN guidelines suggest to check anywhere between 2-12 weeks in patients with thyroid cancer 8

Radioactive iodine ablation of remnant thyroid tissue may potentially be avoided with a postsurgical stimulated Tg level of \< 1ng/ml in low risk, well-differentiated thyroid cancer9. This practice is not yet approved by the American Thyroid Association, and is less likely to be feasible with no concensus on the timing of the Tg measurement.

The objective of this study is therefore to find the nadir of the unstimulated serum Tg level following total thyroidectomy, and therefore the optimal time for Tg measurement in postoperative surveillance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Benign pathology

We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks

No interventions assigned to this group

Malignant pathology

We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. All patients already planning to undergo total /near total thyroidectomy for reasons unrelated to this study.
2. Age 19 or older

Exclusion Criteria

1. Children \< 19 years
2. Pregnancy
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Nebraska

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Whitney Goldner, MD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Patel A, Shostrom V, Treude K, Lydiatt W, Smith R, Goldner W. Serum Thyroglobulin: Preoperative Levels and Factors Affecting Postoperative Optimal Timing following Total Thyroidectomy. Int J Endocrinol. 2019 Feb 20;2019:1384651. doi: 10.1155/2019/1384651. eCollection 2019.

Reference Type DERIVED
PMID: 30915112 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0594-14-FB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Postoperative Hyperthyroidism
NCT01095341 COMPLETED
Early Levothyroxine Post Radioactive Iodine
NCT01950260 COMPLETED PHASE2/PHASE3